Amevive Intramuscular and Imatinib Mesylate
Determining the interaction of Amevive Intramuscular and Imatinib Mesylate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using alefacept together with imatinib may increase the risk of serious infections. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: The use of alefacept with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: Patients receiving other immunosuppressive or myelosuppressive agents or phototherapy should not be treated with alefacept because of the possibility of excessive immunosuppression. The duration of the period following treatment with alefacept before one should consider starting other immunosuppressive therapy has not been evaluated.
- "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.
- CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18
Generic Name: alefacept
Brand name: Amevive
Synonyms: Amevive
Generic Name: imatinib
Brand name: Gleevec
Synonyms: Imatinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Amevive Intramuscular-Imbruvica
- Amevive Intramuscular-Imbruvica (Ibrutinib Capsules)
- Amevive Intramuscular-Imbruvica (Ibrutinib Tablets)
- Amevive Intramuscular-Imdur
- Amevive Intramuscular-Imdur ER
- Amevive Intramuscular-Imfinzi
- Imatinib Mesylate-Amicar
- Imatinib Mesylate-Amicar (Aminocaproic Acid Oral Liquid)
- Imatinib Mesylate-Amicar (Aminocaproic Acid Tablets)
- Imatinib Mesylate-Amicar Intravenous
- Imatinib Mesylate-Amidate
- Imatinib Mesylate-Amifampridine